Oslo, Norway, April 17th 2009.
Please find enclosed an invitation to the Annual general meeting at Photocure ASA on April 29th 2009, attendance slip, proxy form (English and Norwegian) and Annual report 2008 (Norwegian).
Best regards,
Christian Fekete, CFO
Please find enclosed an invitation to the Annual general meeting at Photocure ASA on April 29th 2009, attendance slip, proxy form (English and Norwegian) and Annual report 2008 (Norwegian).
Best regards,
Christian Fekete, CFO
Photocure ASA
Hoffsveien 48
0377 Oslo, Norway
Telephone: +47 22 06 22 10
Telefax: +47 22 06 22 18
www.photocure.com
Photocure ASA is a Norwegian pharmaceutical company listed on Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices for the treatment and diagnosis of different types of cancer. The products are based on proprietary photodynamic technologies, targeting specific dermatology and oncology markets.
Photocure has currently two pharmaceutical products on the market: Metvix®, for the treatment of sun-damaged skin and certain types of skin cancer, and Hexvix®, for the diagnosis of bladder cancer. In addition, the company has developed a proprietary light source, the Aktilite® lamp, which is used in combination with the Metvix cream.
Through worldwide studies, Photocure is continuously testing its products for new indications, and the aim is to develop a pipeline of follow-on products and technologies.
Photocure®, Metvix®, Hexvix® and Aktilite® are registered trademarks of Photocure ASA.
